Premium
Removal of neutrophil gelatinase‐associated lipocalin by extracorporeal therapies
Author(s) -
BOBEK Ilona,
GONG Dehua,
DE CAL Massimo,
CRUZ Dinna,
CHIONH Chang Y.,
HAAPIO Mikko,
SONI Sachin S.,
NALESSO Federico,
LENTINI Paolo,
GARZOTTO Francesco,
CORRADI Valentina,
RONCO Claudio
Publication year - 2010
Publication title -
hemodialysis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.658
H-Index - 47
eISSN - 1542-4758
pISSN - 1492-7535
DOI - 10.1111/j.1542-4758.2010.00452.x
Subject(s) - medicine , neutrophil gelatinase associated lipocalin , hemodialysis , extracorporeal , lipocalin , intensive care medicine , gelatinase , extracorporeal circulation , matrix metalloproteinase
Neutrophil gelatinase‐associated lipocalin (NGAL) protein is an early biomarker for acute kidney injury (AKI). It is unknown if extracorporeal therapies (EC) have an effect on circulating NGAL levels. This study was designed to describe the kinetics of NGAL molecule in different EC techniques and to evaluate NGAL clearance in different operational conditions. A mock hemofiltration (HF) and hemoperfusion (HP) setup was used. NGAL was added to the blood reservoir and then measured at 30‐minute intervals from arterial, venous, and ultrafiltrate (UF) lines. Removal kinetics and NGAL sieving coefficient were calculated. In our experiments, baseline NGAL concentration averaged 452 μg/L. There was a consistent downward trend throughout the experiment. NGAL concentration in the UF was between 80 and 90 μg/L, though it showed a slight increase in the second hour. The sieving coefficient of NGAL ranged from 0.2 to 0.4 during HF and it appeared to increase with time, suggesting an initial effect of membrane adsorption. HP proved clearly that there was adsorption of NGAL by the membrane and the point of saturation occured at approximately 60 minutes from the start of circulation. Our evaluation demonstrates that NGAL can be adsorbed and ultrafiltrated with polysulfone membranes. This should be taken into consideration when using NGAL as an AKI biomarker in patients undergoing EC circulation.